fast track designation – Discover Pharma

Welcome to Discover Pharma! Today is : May 3, 2026

fast track designation

Cardiovascular diseases,Clinical Trials,Rare Diseases
Rare Disease Day 2026: Cereno Scientific advances disease-modifying therapies in PAH
As Rare Disease Day 2026 shines a spotlight on patients [...]

February 27, 2026
Central Nervous System,Clinical Development,Clinical Trials,Drug Development,FDA,Pharmaceuticals and therapeutics,Precision medicine,Research & Development
Alto Neuroscience completes Phase 2 enrollment for ALTO-101 in cognitive impairment associated with schizophrenia
Alto Neuroscience has completed patient enrollment in its Phase 2 [...]

February 13, 2026
Biologics & Biosimilars,Clinical Development,Clinical Trials,Drug approval,Infectious Diseases,Pharmaceuticals and therapeutics,Regulatory Affairs,RNA Therapeutics
Cidara Therapeutics receives FDA Breakthrough Therapy designation for CD388 in seasonal influenza prevention
Cidara Therapeutics has received Breakthrough Therapy designation from the US [...]

October 10, 2025
Cell & Gene Therapy,Clinical Development,Regulatory Affairs
Nanoscope Therapeutics begins FDA submission for gene-agnostic therapy to treat retinitis pigmentosa
Nanoscope Therapeutics has initiated a rolling submission for its Biologics [...]

July 15, 2025
Biologics & Biosimilars,Precision medicine,Regulatory Affairs
Protagonist and Takeda present VERIFY data on rusfertide showing strong results in polycythemia vera
Protagonist and Takeda have shared full 32-week results from the [...]

June 2, 2025

main menu

get connected

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK